SpaceX IPO Could Become Largest in History with $1.8 Trillion Valuation Target 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Synopsys Q2 FY2026 Earnings Beat Driven by AI and Semiconductor Demand 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
NIO CEO Says China’s Auto Industry Has Passed Its Golden Era Amid Weak Car Sales 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
SK Hynix Joins $1 Trillion Club as AI Chip Demand Fuels Stock Surge 
Universal Music Group Rejects Pershing Square Takeover Proposal 
MongoDB Q1 FY2027 Earnings Beat Expectations, Raises Full-Year Outlook 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
US Quantum Stocks Surge After $2 Billion Government Investment 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Mega IPOs Like SpaceX and OpenAI Could Reshape S&P 500 and Nasdaq 100 Portfolios in 2026 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
JPMorgan Sees Biotech Sector at Turning Point, Upgrades Top Pharma Stocks 
Activist investor Starboard Value has fully exited its position in Pfizer, marking the end of a high-profile effort to pressure the pharmaceutical giant into boosting its flagging share price. According to a recent 13-F regulatory filing, Starboard sold approximately 8.5 million Pfizer shares during the third quarter, unwinding a stake that once totaled 15.4 million shares at the end of Q4 2024.
Starboard initially made waves when it disclosed a roughly $1 billion investment in Pfizer a year ago, stepping in at a time when the company’s stock was trading at roughly half its peak during the pandemic. The fund’s founder, Jeffrey Smith, was outspoken about Pfizer’s performance, arguing at an industry event that the board needed to hold management accountable for persistent underperformance and weak market confidence.
Despite its push for governance and operational improvements, Starboard’s campaign struggled to gain lasting traction. The firm had approached former Pfizer executives—including former CEO Ian Read—for strategic guidance, but discussions reportedly stalled. Pfizer’s current market value sits around $142 billion, a decline from roughly $162 billion when Starboard’s involvement was first revealed in October 2024.
Starboard, known for its aggressive activist strategies, has been active across several industries this year, taking positions in companies such as TripAdvisor, Rogers, and BILL Holdings, where it secured a board seat shortly after investing. However, its Pfizer exit marks a notable retreat from what was once one of its most closely watched campaigns.
The same filing also revealed that Starboard fully divested from Fortrea Holdings, a contract research organization spun off from LabCorp in 2023. The hedge fund sold 2.5 million Fortrea shares during the third quarter. Since Starboard disclosed its investment in October 2023, Fortrea’s share price has fallen nearly 50%, adding another setback to the fund’s recent positions.
Starboard declined to comment on the latest disclosures.
